Johnson & Johnson (JNJ.US) shares are gaining 4% during today's session, after the drug and healthcare products manufacturer reported second-quarter results that exceeded analysts' expectations. On the other hand, the company lowered its adjusted earnings per share forecast for the full year due to costs associated with mergers and acquisitions resulting from recent transactions. However, it seems that in the eyes of investors, higher costs incurred now will be offset by higher profits in the future.
ANNUAL FORECAST
- Expected adjusted earnings per share (EPS) $9.97 to $10.07, previously $10.57 to $10.72
- Expected adjusted operating EPS $10 to $10.10, previously $10.60 to $10.75
- Expected revenues between $88 billion to $88.4 billion (unchanged)
SECOND QUARTER RESULTS
- Adjusted EPS $2.82, estimated $2.71
- Revenues $22.45 billion, estimated $22.32 billion
- MedTech revenues $7.96 billion, estimated $8.22 billion
- Pharmaceutical division revenues $14.49 billion, estimated $14.08 billion
Source: xStation
Daily Summary: U.S. stock indices are climbing following the PPI data
AI needs power and that’s where the profits are. Oracle and Bloom set the path.
US OPEN: Wall Street Rallies on Soft PPI Data
Novo Nordisk announces a strategic partnership with OpenAI🧬🤖